Dr Joseph L Bizek, MD in Aurora, MO - Surgery

Dr Joseph L Bizek, MD is a Surgery physician based in Aurora, Missouri. Dr Joseph L Bizek is licensed to practice in Missouri (license number R6113) and his current practice location is 500 Porter Ave, Aurora, Missouri. He can be reached at his office (for appointments etc.) via phone at (417) 678-2122.

NPI number for Dr Joseph L Bizek is 1710028311 and his current mailing address is 500 Porter Ave, Aurora, Missouri. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1710028311.

Contact Information

	Dr Joseph L Bizek, MD
	500 Porter Ave, Aurora, MO 65605-2365
	(417) 678-2122
	(417) 678-7877

Physician's Profile

Full Name	Dr Joseph L Bizek
Gender	Male
Speciality	Surgery
Location	500 Porter Ave, Aurora, Missouri
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1710028311
Provider Enumeration Date: 02/08/2007
Last Update Date: 07/22/2008

Medical Identifiers

Medical identifiers for Dr Joseph L Bizek such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1710028311	NPI	-	NPPES
83752	Other	MO	AR BLUE SHIELD #
207519208	Medicaid	MO

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208600000X	Surgery	R6113 (Missouri)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Joseph L Bizek is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Joseph L Bizek, MD 500 Porter Ave, Aurora, MO 65605-2365 Ph: (417) 678-2122	Dr Joseph L Bizek, MD 500 Porter Ave, Aurora, MO 65605-2365 Ph: (417) 678-2122

News Archive

GenVec reports net loss of $1.5 million for first quarter 2015

GenVec, Inc. today reported financial results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, GenVec reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.4 million, compared with a net loss of $1.0 million, or $0.07 per share, on revenues of $2.1 million, for the same period in the prior year.

Scientists reveal how TREX proteins act as passport for transfer of cell blueprints

Decoded process could hold the key to future treatments for a wide range of chronic health problems including Motor Neuron Disease, myotonic dystrophy and a wide range of cancers, University of Sheffield scientists have revealed.

Reported failure of vitamin E to prevent heart attacks may be due to underdosing

The findings, published early online in Free Radical Biology and Medicine, suggest that these earlier studies all had a fundamental flaw the doses used werent high enough to have a significant antioxidant effect.

House Republicans promise new efforts to fight health law's individual mandate

Speaker John Boehner vows to hold a vote this month to remove the requirement that Americans get insurance, and some in the GOP suggest they could attach the effort to bills raising the U.S. debt limit.

Alnylam Pharmaceuticals receives 'Notice of Allowance' from USPTO

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the "Soutschek and Manoharan" patent (Application No. 10/916,185), which covers certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates for in vivo delivery.

Dr Joseph L Bizek, MD - Surgery in Aurora, MO